PRAMEF6: A Potential Drug Target and Biomarker (G440561)

Target Name: PRAMEF6

NCBI ID: G440561

PRAMEF6

Other Name(s): PRAME family member 6 | PRAM6_HUMAN

PRAMEF6: A Potential Drug Target and Biomarker

Pramef6, also known as PRAMEF6-1, is a protein that is expressed in various tissues and organs, including the brain, heart, and kidneys. Its full name is primate-restricted membrane-associated protein 6. PRAMEF6 is a member of the PRAME family, which includes proteins that are involved in various cellular processes, including cell signaling, inflammation, and stress responses.

The PRAMEF6 gene was first identified in 2004, and since then, researchers have made significant progress in understanding its function and potential as a drug target. Studies have shown that PRAMEF6 is involved in various physiological processes, including the regulation of ion channels, neurotransmitter signaling, and stress responses.

One of the key functions of PRAMEF6 is its role in the regulation of ion channels. These channels play a crucial role in the transmission of electrical signals in the brain and other nervous cells. PRAMEF6 is known to be involved in the regulation of the K+ and Na+ channels, which are important for neuronal signaling.

In addition to its role in ion channels, PRAMEF6 is also involved in the regulation of neurotransmitter signaling. These signaling molecules are important for transmitting information between neurons and other cells in the nervous system. PRAMEF6 is known to be involved in the regulation of dopamine, serotonin, and other neurotransmitters.

PRAMEF6 is also involved in the regulation of stress responses. Stress can have a negative impact on the body, leading to various diseases, including anxiety, depression, and neurodegenerative disorders. PRAMEF6 is known to be involved in the regulation of stress responses, including the regulation of corticosteroids, which are important for stress responses.

As a potential drug target, PRAMEF6 is of interest because of its involvement in various physiological processes that are important for human health. For example, the regulation of ion channels, neurotransmitter signaling, and stress responses are important for maintaining the normal function of the brain and other nervous cells. If PRAMEF6 can be targeted with drugs, it may be useful for the treatment of various neurological and psychiatric disorders.

In addition to its potential drug-targeting properties, PRAMEF6 is also a potential biomarker. The regulation of ion channels, neurotransmitter signaling, and stress responses is often associated with certain diseases, including Alzheimer's disease, Parkinson's disease, and other neurological disorders. By studying the regulation of these processes, researchers may be able to develop new diagnostic tools and treatments for these disorders.

Overall, PRAMEF6 is a protein that is expressed in various tissues and organs, and its full name is primate-restricted membrane-associated protein 6. It is involved in various physiological processes, including the regulation of ion channels, neurotransmitter signaling, and stress responses. As a potential drug target and biomarker, PRAMEF6 is of interest for the development of new therapeutic approaches for the treatment of various neurological and psychiatric disorders.

Protein Name: PRAME Family Member 6

Functions: Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation (PubMed:26138980). The CRL2(PRAMEF6) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding (PubMed:26138980)

The "PRAMEF6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRAMEF6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets